CClinicalTrials.gg
Sign In
Active, not recruitingNCT04983225Updated May 31, 2023

The Safety and Tolerability of Initial Periodontal Therapy Combined With Human Dental Pulp Stem Cell Injection in the Treatment of Chronic Periodontitis

A Phase 1 interventional study of Human Dental Pulp Stem Cells and Saline solution in Periodontitis, sponsored by Peking University Third Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-31.

Sponsored by Peking University Third Hospital · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 2 months ago, but the record still lists the study as active, not recruiting.
Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The principal objective of this trial is to investigate the safety and tolerability of human dental pulp stem cells injection in the treatment of chronic periodontitis. The secondary objective is to provide the basis for dosage regimen for further clinical trials and to evaluate the preliminary efficacy.

Read the detailed description

Initial periodontal therapy involves cleaning, scaling and root planing. The present dose-escalating, randomized, double-blind, blank controlled clinical trial will be conducted to evaluate the safety and tolerability of dental pulp mesenchymal stem cells injection as an adjunct with Initial periodontal therapy in chronic periodontitis. Patients meeting the inclusion criteria will be assigned into five dose groups, in a 3:1 ratio within each group to treat with drug or placebo after initial periodontal therapy. The evaluation will be conducted based on safety and efficacy end points.

02

Conditions studied

  • Periodontitis

Keywords

  • Human Dental Pulp Stem Cell
03

In context

Periodontitis

1,635 studies on the registry are indexed under Periodontitis; 327 are open to participants now.

This study's planned enrollment of 36 is below the median of 45 across 1,191 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 735 studies on the registry; 262 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 to 65 years old (including threshold ), unlimited gender.
  • Radiological examination of the periodontal defect site shows vertical bone defect, and the probing depth (PD) is 4 to 8 mm.
  • Voluntarily participate in the clinical study, understand and sign the informed consent, and comply with the relevant regulations during the study period and within 18 months after the end of the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects with severe periodontal diseases (alveolar bone resorption generally exceeds two-thirds of the tooth root length) and affects the study tooth judgment;
  • The grade of studied tooth looseness ≥ grade 2 (only buccolingual movement is defined as grade 1; buccolingual and mesiodistal movement is grade 2; vertical loosening is grade 3);
  • Subjects with surgical treatment of previous periodontal bone defect sites and adjacent periodontal tissues;
  • Subjects with non-steroid anti-inflammatory drug, steroid hormone therapy, and/or hormone (except topical hormones) treatment, bisphosphonates within the previous 3 months before screening;
  • Subjects with severe systemic infection within the previous 3 months before screening; or antibiotics treatment within 72 h before screening;
  • Subjects with uncontrolled hypertension within 1 month before screening (defined as sitting systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg after receiving the optimal antihypertensive therapy);
  • Subjects with systemic diseases (including but not limited to: malignant tumor or with positive tumor examination during screening, diabetes, heart failure caused by heart disease, myocardial infarction within the first 6 months before screening, angina symptoms within the first 6 months before screening, and congenital heart disease, etc.);
  • Subjects who are known to be allergic to any of the materials used in the treatment;
  • Subjects with the allergic constitution and previous history of allergy to blood products;
  • Laboratory test (any of them meets): abnormal liver function: ALT > 80 U/L or AST > 70 U/L; abnormal renal function: serum creatinine (picric acid method) > 97 μmol/L;
  • Subjects with a bleeding tendency or coagulant dysfunction (INR ≥ 1.5 × ULN, or APTT ≥ 1.5 × ULN (except the ones who are receiving anticoagulant therapy)) or serious hematologic diseases (such as grade 3 or above anemia (Hb \< 80 g/L); grade 2 or above thrombocytopenia ( \< 75.0 × 109 /L))
  • Viral serology positive (HBsAg, HCV antibody, HIV antibody, treponema pallidum antibody) positive;
  • Subjects with unprotected sex within the previous 1 month before the screening;
  • Pregnant or lactating women, or subjects with a positive result of β-HCG before the screening, or subjects who are unable or unwilling to take contraceptive measures under the investigator instruction;
  • Women with oral contraceptives;
  • Subjects with a history of smoking addiction in the previous 12 months before the screening (the number of cigarettes smoked per day ≥ 10);
  • Subjects with mental or conscious disorders;
  • Subjects who participated in other clinical studies within 3 months before the screening;
  • Other circumstances deemed inappropriate by the investigator.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    1×10^6 cells/site group

    Human Dental Pulp Stem Cells Injection: 1×10\^6 cells/periodontal defect site.

    Drug: Human Dental Pulp Stem Cells

  • Experimental
    5×10^6 cells/site group

    Human Dental Pulp Stem Cells Injection: 5×10\^6 cells/periodontal defect site.

    Drug: Human Dental Pulp Stem Cells

  • Experimental
    1×10^7 cells/site group

    Human Dental Pulp Stem Cells Injection: 1×10\^7 cells/periodontal defect site.

    Drug: Human Dental Pulp Stem Cells

  • Experimental
    2×10^7 cells/two sites group

    Human Dental Pulp Stem Cells Injection: 1×10\^7 cells/periodontal defect site, two locations in total, and the total cell injection volume is 2 × 10\^7 cells/2 periodontal defect sites.

    Drug: Human Dental Pulp Stem Cells

  • Experimental
    3~4×10^7 cells/three or four sites group

    Human Dental Pulp Stem Cells Injection: 1×10\^7 cells/periodontal defect site, three or four locations in total, and the total cell injection volume is 3 × 10\^7 to 4 × 10\^7 cells/3 to 4 periodontal defect sites.

    Drug: Human Dental Pulp Stem Cells

  • Placebo comparator
    Saline solution group

    Saline solution: 0.6mL/periodontal defect site.

    Other: Saline solution

Interventions

  • DrugHuman Dental Pulp Stem Cells

    Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;

    Also known as: Initial periodontal therapy

  • OtherSaline solution

    Blank control: initial Basal periodontal therapy (supragingival cleansing, subgingival scaling and root planning) followed by a single local injection of normal saline.

    Also known as: Initial periodontal therapy

06

What researchers measure

Primary outcomes

  1. Changes from baseline in respiration rate of Vital Signs.

    Respiration rate in mg(μl)/(h·g)

    Time frame: within 180 days after administration.

  2. Changes from baseline in heart rate of Vital Signs.

    Heart rate in beats per minute

    Time frame: within 180 days after administration.

  3. Changes from baseline in blood pressure of Vital Signs.

    Blood pressure in mmHg

    Time frame: within 180 days after administration.

  4. Changes from baseline in body temperature of Vital Signs.

    Body temperature in Celsius degree

    Time frame: within 180 days after administration.

  5. Changes from baseline in red blood cell count of Laboratory Examination

    Red blood cell count in whole blood is reported in the form of number.

    Time frame: within 180 days after administration.

  6. Changes from baseline in white blood cell count of Laboratory Examination

    White blood cell count in whole blood is reported in the form of number.

    Time frame: within 180 days after administration.

  7. Changes from baseline in neutrophil count of Laboratory Examination

    Neutrophil count in whole blood is reported in the form of number.

    Time frame: within 180 days after administration.

  8. Changes from baseline in lymphocyte count of Laboratory Examination

    Lymphocyte count in whole blood is reported in the form of number.

    Time frame: within 180 days after administration.

  9. Changes from baseline in platelet count of Laboratory Examination

    Platelet count in whole blood is reported in the form of number.

    Time frame: within 180 days after administration.

  10. Changes from baseline in hemoglobin of Laboratory Examination

    Changes of hemoglobin concentration（g/dL）in whole blood will be recorded.

    Time frame: within 180 days after administration.

  11. Changes from baseline in PT of Laboratory Examination

    Prothrombin time (PT) is a screening test for exogenous coagulation factors.

    Time frame: within 180 days after administration.

  12. Changes from baseline in INR of Laboratory Examination

    International standardized ratio (INR) is calculated from prothrombin time and international sensitivity index (ISI) of the reagent.

    Time frame: within 180 days after administration.

  13. Changes from baseline in APTT of Laboratory Examination

    Activated partial thromboplastin time (APTT) is a screening test for endogenous coagulation factors.

    Time frame: within 180 days after administration.

  14. Changes from baseline in total bilirubin of Laboratory Examination

    Changes of total bilirubin concentration (μmol/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  15. Changes from baseline in direct bilirubin of Laboratory Examination

    Changes of direct bilirubin concentration (μmol/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  16. Changes from baseline in ALT of Laboratory Examination

    Changes of ALT concentration (U/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  17. Changes from baseline in AST of Laboratory Examination

    Changes of AST concentration (U/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  18. Changes from baseline in total protein of Laboratory Examination

    Changes of total protein concentration (g/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  19. Changes from baseline in albumin of Laboratory Examination

    Changes of albumin concentration (g/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  20. Changes from baseline in total bile acid of Laboratory Examination

    Changes of total bile acid concentration (μmol/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  21. Changes from baseline in urea of Laboratory Examination

    Changes of urea concentration (mmol/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  22. Changes from baseline in creatinine of Laboratory Examination

    Changes of creatinine concentration (μmol/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  23. Changes from baseline in uric acid of Laboratory Examination

    Changes of uric acid concentration (μmol/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  24. Changes from baseline in glucose of Laboratory Examination

    Changes of glucose concentration (mmol/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  25. Changes from baseline in potassium of Laboratory Examination

    Changes of potassium concentration (mmol/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  26. Changes from baseline in sodium of Laboratory Examination

    Changes of sodium concentration (mmol/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  27. Changes from baseline in chlorine of Laboratory Examination

    Changes of chlorine concentration (mmol/L) in serum will be recorded.

    Time frame: within 180 days after administration.

  28. Changes from baseline in CPR of Laboratory Examination

    C-reactive protein (CPR) is a phylogenetically highly conserved plasma protein, changes of its plasma concentration（mg/L）will be recorded.

    Time frame: within 180 days after administration.

  29. Changes from baseline in Detection of infectious diseases of Laboratory Examination

    It refers to infectious diseases screening.

    Time frame: within 180 days after administration.

  30. Changes from baseline in IgA of Laboratory Examination

    Changes of IgA concentration （g/L）in serum will be recorded.

    Time frame: within 180 days after administration.

  31. Changes from baseline in IgG of Laboratory Examination

    Changes of IgG concentration （g/L）in serum will be recorded.

    Time frame: within 180 days after administration.

  32. Changes from baseline in IgM of Laboratory Examination

    Changes of IgM concentration （g/L）in serum will be recorded.

    Time frame: within 180 days after administration.

  33. Changes from baseline in total IgE of Laboratory Examination

    Changes of total IgE concentration （g/L）in serum will be recorded.

    Time frame: within 180 days after administration.

  34. Changes from baseline in Pregnancy test of Laboratory Examination

    Pregnancy test will be tested in female subjects

    Time frame: within 180 days after administration.

  35. Changes from baseline in urine specific gravity of Laboratory Examination

    Changes of urine specific gravity will be recorded.

    Time frame: within 180 days after administration.

  36. Changes from baseline in urine pH of Laboratory Examination

    Changes of urine pH value will be recorded.

    Time frame: within 180 days after administration.

  37. Changes from baseline in urine glucose of Laboratory Examination

    Changes of urine glucose will be examined by qualitative test (positive or negative).

    Time frame: within 180 days after administration.

  38. Changes from baseline in urine protein of Laboratory Examination

    Changes of urine protein will be examined by qualitative test (positive or negative).

    Time frame: within 180 days after administration.

  39. Changes from baseline in urine ketone body of Laboratory Examination

    Changes of urine ketone body will be examined by qualitative test (positive or negative).

    Time frame: within 180 days after administration.

  40. Changes from baseline in urine white blood cell of Laboratory Examination

    Changes of white blood cell in urine will be examined by qualitative test (positive or negative).

    Time frame: within 180 days after administration.

  41. Changes from baseline in urine bilirubin of Laboratory Examination

    Changes of urine bilirubin will be examined by qualitative test (positive or negative).

    Time frame: within 180 days after administration.

  42. Changes from baseline in urine occult blood of Laboratory Examination

    Changes of urine occult blood will be examined by qualitative test (positive or negative).

    Time frame: within 180 days after administration.

  43. Changes from baseline in stool form of Laboratory Examination

    Stool form is classified by Bristol Stool Form Scale into 7 categories scored from 1 to 7; (1) Separate hard lumps like nuts (difficult to pass); (2) Sausage-shaped but lumpy; (3) Like a sausage but with cracks on its surface; (4) Like a sausage or snake, smooth and soft; (5) Soft blobs with clear-cut edges (passed easily); (6) Fluffy pieces with ragged edges, a mushy stool; (7) Watery, no solid pieces, entirely liquid.

    Time frame: within 180 days after administration.

  44. Changes from baseline in stool white blood cells of Laboratory Examination

    White blood cell count in stools is reported in the form of number.

    Time frame: within 180 days after administration.

  45. Changes from baseline in stool red blood cells of Laboratory Examination

    Red blood cell count in stools is reported in the form of number.

    Time frame: within 180 days after administration.

  46. Changes from baseline in stool parasite egg of Laboratory Examination

    Parasite egg count in stools is reported in the form of number.

    Time frame: within 180 days after administration.

  47. Changes from baseline in stool OBT of Laboratory Examination

    Changes of stool OBT will be examined by qualitative test (positive or negative).

    Time frame: within 180 days after administration.

  48. Changes from baseline in ECG

    The cardiac rhythm is showed in ECG in the form of continuous curve. Changes of this continuous curve will be recorded.

    Time frame: within 180 days after administration.

  49. Incidence of Treatment-Emergent Adverse Event

    Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events during the study period, and the severity of adverse events is determined according to the NCI CTCAE version 5.0.

    Time frame: within 180 days after administration.

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Event

    Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events within 360 days and 720 days after administration, and the severity of adverse events is determined according to the NCI CTCAE version 5.0.

    Time frame: within 360 days and 720 days after administration

  2. Change from baseline in Clinical Attachment Level (AL).

    Clinical Attachment Level (AL) may be assessed to the nearest millimeter by means of a graduated probe and expressed as the distance in millimeters from the CEJ to the bottom of the probeable gingival/periodontal pocket. The clinical assessment requires the measurement of the distance from the free gingival margin (FGM) to the CEJ for each tooth surface. After this recording, AL may be calculated from the periodontal chart (i.e. PPD - distance CEJ to FGM). In cases with gingival recession, the distance FGM-CEJ turns negative and, hence, will be added to the PPD to determine AL.

    Time frame: at baseline, 90 days, 180 days ,360 days, 720 days.

  3. Change from baseline in Probing Depth (PD).

    The probing depth is the distance from the gingival margin to the bottom of the gingival sulcus/pocket, is measured to the nearest millimeter by means of periodontal probe.

    Time frame: at baseline, 90 days, 180 days ,360 days, 720 days.

  4. Change from baseline in Probing Bleeding Index （BI）

    A periodontal probe is inserted to the "bottom" of the gingival/periodontal pocket applying light force and is moved gently along the tooth (root) surface. If bleeding is provoked by this examination, the site examined is considered bleeding on probing-positive and, hence, inflamed. Probing Bleeding Index is divided into 5 grades: 0, 1, 2, 3 and 4.

    Time frame: at baseline, 90 days, 180 days ,360 days, 720 days.

  5. Change from baseline in Gingival recession （GR）

    Exposure of the tooth through apical migration of the gingiva is called gingival recession. Recorded as the distance in millimeters from the CEJ to the gingival margin.

    Time frame: at baseline, 90 days, 180 days ,360 days, 720 days.

  6. Change from baseline in Tooth Mobility (TM).

    The continuous loss of the supporting tissues during periodontal disease progression may result in increased tooth mobility, which is divided into 3 degree: I°, II°, and III°. Changes from baseline in tooth mobility will be recorded.

    Time frame: at baseline, 90 days, 180 days ,360 days, 720 days.

  7. Changes from baseline in height of the periodontal bone defect and average density of alveolar ridge.

    Changes in the height of the periodontal bone defect and the mean alveolar ridge density will be detected by Cone Beam Computed Tomography (CBCT)

    Time frame: at baseline, 90 days, 180 days ,360 days, 720 days.

07

Study locations

1 site
  • Peking University Third Hospital
    Beijing, Beijng 100191, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04983225
Lead sponsor
Peking University Third Hospital
Collaborators
Capital Medical University
Responsible party
Sponsor
First posted
Jul 30, 2021
Start date
Jul 31, 2021
Primary completion
Jul 31, 2024 (estimated)
Completion
Aug 31, 2024 (estimated)
Last update
May 31, 2023

Study contacts

Xiao Wang, Master
principal investigator · Department of Stomatology, Peking University Third Hospital, Beijing, China.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Periodontitis→

Other studies from this sponsor

Peking University Third Hospital

Start the discussion